Advertisement Elastin Specialties to partner with Novozymes - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Elastin Specialties to partner with Novozymes

Elastin Specialties has formalized an agreement with Novozymes of Denmark to combine resources for identifying and securing commercial parties to market their protein-based products.

Elastin Specialties holds patents around the production and use of proteins based on human elastin sequences and proteins of similar type. Key attributes of these proteins is that they self-assemble and can be used to make a variety of biomaterials, useful as coatings or as composite materials. Novozymes possesses considerable expertise in the production of proteins and is recognized as a major player at the multi-national level.

Novozymes role in the venture will be to scale and eventually manufacture finished protein for sale to third-party entities while Elastin Specialties will continue to pursue and expand uses at the R&D stages.

Steven Rothstein, president of Elastin Specialties, said: “These products will satisfy largely un-met needs and will certainly offer significant competitive advantages. The size, resources and capability of a partner such as Novozymes will allow us to move such products from early development to market with the assurance of an experienced manufacturing partner.”